Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > LATEST
LATEST
-
ARCHIVE MEDICAL DEVICE NEWS IN BRIEF
November 10, 2003
-
ARCHIVE Support for Bungyo Stronger in Patients Who Have Experienced It
November 10, 2003
-
ARCHIVE WORLD NEWS IN BRIEF
November 10, 2003
-
ARCHIVE BULLETIN
November 10, 2003
-
ARCHIVE Japanese Healthcare Q&A (3)
November 10, 2003
-
ARCHIVE MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
November 10, 2003
-
ARCHIVE Nearly 70% of Women Worry about Adverse Reactions of Oral Contraceptives
November 10, 2003
-
ARCHIVE Hayashibara Develops Peptide Antigens for Transmucosal Administration
November 10, 2003
-
COMMENTARY
November 10, 2003
-
ARCHIVE Long-term Monitoring Required after H. Pylori Eradication
November 10, 2003
-
ARCHIVE Debiopharm Preparing to Enter Japanese Market: Dr Mauvernay
November 10, 2003
-
ARCHIVE Crucial Info Should Be Printed Larger on Drug Labels: Study
November 10, 2003
-
ARCHIVE FJPWA Management Seminar
November 10, 2003
-
ARCHIVE RESEARCH & DEVELOPMENT NEWS IN BRIEF
November 10, 2003
-
ARCHIVE WLJ to Change Its Name to Wyeth K.K.
November 10, 2003
-
ARCHIVE OTC NEWS IN BRIEF
November 10, 2003
-
ARCHIVE 2nd Pharmaceutical Industry Business Model Research Forum
November 10, 2003
-
ARCHIVE DIAGNOSTIC NEWS IN BRIEF
November 10, 2003
-
ARCHIVE BULLETIN
November 10, 2003
-
ARCHIVE Asahi Medical to Increase Production of APS Artificial Kidneys
November 10, 2003
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…